(Q38236774)

English

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus

scientific article published on September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 August 2017

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

31 August 2017

1 reference

based on heuristic

inferred from title

chronic liver disease

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

André J Scheen

1

1 reference

Europe PubMed Central

31 August 2017

publication date

1 September 2014

1 reference

Europe PubMed Central

31 August 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

31 August 2017

53

1 reference

Europe PubMed Central

31 August 2017

9

1 reference

Europe PubMed Central

31 August 2017

773-785

1 reference

Europe PubMed Central

31 August 2017

https://scigraph.springernature.com/pub.10.1007/s40262-014-0157-y

0 references

Diabetes in chronic liver disease: from old concepts to new evidence

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Liver and diabetes. A vicious circle

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Impact of liver diseases on the development of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Glucose and insulin metabolism in cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

The role of metformin in the management of NAFLD

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

A review of gliptins in 2011.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Elevated hepatic enzymes potentially associated with sitagliptin

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Drug-related hepatotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Saxagliptin overview: special focus on safety and adverse effects

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Pharmacokinetics of linagliptin in subjects with hepatic impairment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Probable linagliptin-induced liver toxicity: a case report

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto Prefecture

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Investigation of exenatide elimination and its in vivo and in vitro degradation.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Liraglutide-induced autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Dipeptidyl peptidase-4: a key player in chronic liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0157-Y

21 January 2018

Renal failure in chronic liver disease and the hepatorenal syndrome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatogenous diabetes. Current views of an ancient problem.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dipeptidyl peptidase IV (DDP IV) in NASH patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Managing diabetes in patients with chronic liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A case of drug-induced hepatic injury associated with sitagliptin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25091053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-014-0157-Y

1 reference

Europe PubMed Central

31 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

31 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38236774&oldid=2116894944"